Radiopharm Theranostics (RADX) News
NASDAQ: RADXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RADX news summary
We found 5 recent headlines mentioning Radiopharm Theranostics (RADX): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire. RADX is making an outsized move today, down 9.71% at $0.6304, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Radiopharm Theranostics Limited - Depositary Receipt Price Target Increased by 10.97% to $14.67", was published by Nasdaq on Nov 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Radiopharm Theranostics headlines
- Radiopharm Theranostics Limited - Depositary Receipt Price Target Increased by 10.97% to $14.67The average one-year price target for Radiopharm Theranostics Limited - Depositary Receipt (NASDAQCM:RADX) has been revised to $14.67 / share. This is an increase of 10.97% from the prior estimate of…Nasdaq
- Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain MetastasesSingle, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholdsGlobeNewswire
- Radiopharm Aligns With FDA On Single Pivotal Phase 3 RAD101 Trial For Brain Metastases(RTTNews) - Radiopharm Theranostics Ltd. (RADX) said Wednesday it received the final minutes of its end-of-Phase 2 meeting with the U.S. Food and Drug Administration, confirming agreement on the…NasdaqRADX, HEI.A
- Radiopharm Theranostics Reports Business UpdatePhase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug AdministrationGlobeNewswire
- GE HealthCare Wins Approval for MINItrace Magni Cyclotron in EuropeGE HealthCare secures CE Mark certification for MINItrace Magni and expands Copper-64 production capabilities, strengthening its PET imaging and theranostics portfolio.NasdaqGEHC, LNTH, TLX, RADX